MT-302

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameMT-302
Drug Alias NameTROP2-FcA LNP(Myeloid Therapeutics)MT-302
ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Donor > Autologous +[5] 
Mechanisms of ActionAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsLung NeoplasmsColonic NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMyeloid Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMyeloid Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsColonic NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A